Regulus Therapeutics (RGLS)

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17, which is currently in a Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. The company has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. to develop, manufacture, and commercialize products covered by the licensed patent rights for use in microRNA compounds. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.